Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $180 from $175 and keeps an Equal Weight rating on the shares after updating the firm’s model for recently reported Q4 results and rolling forward its valuation date.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Yorvipath: Impressive Launch and Strong Growth Potential Drive Buy Rating
- Potential Share Dilution Looms for Ascendis Pharma: What Investors Need to Know
- Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges
- Ascendis Pharma price target raised to $162 from $153 at TD Cowen
- Ascendis Pharma price target lowered to $192 from $203 at BofA